In vivo evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Iranzo J, Martincorena I, Koonin EV. Cancer-mutation network and the number and specificity of driver mutations. Proc. Natl Acad. Sci. USA 115(26), E6010–E6019 (2018).
  Medline CASGoogle Scholar
• 2. Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P. Recent advances in understanding the complexities of metastasis. F1000Res 7, F1000 Faculty Rev-1169 (2018).
  MedlineGoogle Scholar
• 3. Chan KK, Matchett KB, Mcenhill PM et al. Protein deregulation associated with breast cancer metastasis. Cytokine Growth Factor Rev. 26(4), 415–423 (2015).
  Medline CASGoogle Scholar
• 4. Sheng C, Qiu J, Wang Y et al. Knockdown of Ran GTPase expression inhibits the proliferation and migration of breast cancer cells. Mol. Med. Rep. 18(1), 157–168 (2018). • The results provide strong in vitro evidence of the involvement of Ran in the progression of breast cancer and suggest that it could have good potential as a therapeutic target and/or marker of disease.
  Medline CASGoogle Scholar
• 5. Desantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J. Clin. 66(1), 31–42 (2016).
  MedlineGoogle Scholar
• 6. Feng Y, Spezia M, Huang S et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5(2), 77–106 (2018).
  Medline CASGoogle Scholar
• 7. Parker PJ, Kishore U. Editorial: signaling by small GTPases in metastatic disease. Front Cell Dev. Biol. 10, 841572 (2022).
  MedlineGoogle Scholar
• 8. El-Tanani M, Platt-Higgins A, Nsairat H et al. Corrigendum to “Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer” [Life Sci., 329 (2023) 121964]. Life Sci. 331, 122075 (2023). •• Ran biomarker could be used for diagnostic purposes using formalin-fixed, paraffin-embedded tumor biopsy samples from breast cancer patients in the early stages.
  Medline CASGoogle Scholar
• 9. El-Tanani M, Nsairat H, Mishra V et al. Ran GTPase and its importance in cellular signaling and malignant phenotype. Int. J. Mol. Sci. 24(4), 3065 (2023).
  Medline CASGoogle Scholar
• 10. Yuen HF, Chan KK, Grills C et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin. Cancer Res. 18(2), 380–391 (2012). • Ran is a potential therapeutic target for the treatment of cancers with mutations/changes of expression in protooncogenes that lead to activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
  Medline CASGoogle Scholar
• 11. Costa B, Amorim I, Gärtner F, Vale N. Understanding breast cancer: from conventional therapies to repurposed drugs. Eur. J. Pharm. Sci. 151, 105401 (2020).
  Medline CASGoogle Scholar
• 12. Zhang L, Bochkur Dratver M, Yazal T et al. Mebendazole potentiates radiation therapy in triple-negative breast cancer. Int. J. Radiat. Oncol. Biol. Phys 103(1), 195–207 (2019).
  Medline CASGoogle Scholar
• 13. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO) – mebendazole as an anti-cancer agent. eCancerMedicalScience 8, 443 (2014).
  MedlineGoogle Scholar
• 14. Kumar B, Kumar R, Skvortsova I, Kumar V. Mechanisms of tubulin binding ligands to target cancer cells: updates on their therapeutic potential and clinical trials. Curr. Cancer Drug Targets 17(4), 357–375 (2017).
  Medline CASGoogle Scholar
• 15. Sumimoto Y, Okawa S, Inoue T, Masuda K, Maruyama M, Higaki K. Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: disruption of high crystallinity by utilizing its counter ion. Eur. J. Pharm. Biopharm. 172, 213–227 (2022).
  Medline CASGoogle Scholar
• 16. Khater D, Nsairat H, Odeh F et al. Design, preparation, and characterization of effective dermal and transdermal lipid nanoparticles: a review. Cosmetics 8(2), 1–43 (2021).
  Google Scholar
• 17. Nsairat H, Khater D, Odeh F et al. Lipid nanostructures for targeting brain cancer. Heliyon 7(9), e07994 (2021).
  Medline CASGoogle Scholar
• 18. Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials (Basel) 7(6), 122 (2017).
  MedlineGoogle Scholar
• 19. Mehrdadi S. Drug delivery of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to target brain tumors. Adv. Pharm. Bull. 13(3), 512–520 (2023).
  Medline CASGoogle Scholar
• 20. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon 8(5), e09394 (2022).
  Medline CASGoogle Scholar
• 21. Shakya AK, Al-Sulaibi M, Naik RR, Nsairat H, Suboh S, Abulaila A. Review on PLGA polymer-based nanoparticles with antimicrobial properties and their application in various medical conditions or infections. Polymers 15(17), 1–25 (2023).
  Google Scholar
• 22. Nsairat H, Ibrahim AA, Jaber AM et al. Liposome bilayer stability: emphasis on cholesterol and its alternatives. J. Liposome Res. 34(1), 178–202 (2024).
  Medline CASGoogle Scholar
• 23. El-Tanani M, Nsairat H, Aljabali AA, Matalka II, Alkilany AM, Tambuwala MM. Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer. Expert Opin. Drug Deliv. doi:10.1080/17425247.2024.2311812 1–16 (2024). • These carriers offer versatility, enabling the encapsulation and precise targeting of multiple drugs with different modes of action, a crucial advantage when dealing with the complexity of breast cancer treatment.
  MedlineGoogle Scholar
• 24. Jamous YF, Altwaijry NA, Saleem MTS, Alrayes AF, Albishi SM, Almeshari MA. Formulation and characterization of solid lipid nanoparticles loaded with troxerutin. Processes 11(10), 1–18 (2023).
  Google Scholar
• 25. Pezeshki A, Ghanbarzadeh B, Mohammadi M, Fathollahi I, Hamishehkar H. Encapsulation of vitamin A palmitate in nanostructured lipid carrier (NLC) – effect of surfactant concentration on the formulation properties. Adv. Pharm. Bull. 4(Suppl. 2), 563–568 (2014).
  MedlineGoogle Scholar
• 26. Kim SW, Kim SJ, Langley RR, Fidler IJ. Modulation of the cancer cell transcriptome by culture media formulations and cell density. Int. J. Oncol. 46(5), 2067–2075 (2015).
  Medline CASGoogle Scholar
• 27. Lee DY, Lee SY, Yun SH et al. Review of the current research on fetal bovine serum and the development of cultured meat. Food Sci. Anim. Resour. 42(5), 775–799 (2022).
  MedlineGoogle Scholar
• 28. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. Int. J. Mol. Sci. 22(23), 1–30 (2021).
  Google Scholar
• 29. Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. In vitro cell migration and invasion assays. J. Vis. Exp. doi:10.3791/51046(88) (2014).
  MedlineGoogle Scholar
• 30. Martinez-Madrid B, Donnez J, Eyck A-S, Veiga-Lopez A, Dolmans M-M, Van Langendonckt A. Chick embryo chorioallantoic membrane (CAM) model: a useful tool to study short-term transplantation of cryopreserved human ovarian tissue. Fertil. Steril. 91, 285–292 (2008).
  MedlineGoogle Scholar
• 31. Tahergorabi Z, Khazaei M. A review on angiogenesis and its assays. Iran J. Basic Med. Sci. 15(6), 1110–1126 (2012).
  Medline CASGoogle Scholar
• 32. Eh Suk VR, Mohd Latif F, Teo YY, Misran M. Development of nanostructured lipid carrier (NLC) assisted with polysorbate nonionic surfactants as a carrier for l-ascorbic acid and Gold Tri.E 30. J. Food Sci. Technol. 57(9), 3259–3266 (2020).
  MedlineGoogle Scholar
• 33. Yang S, Gong P, Pan J et al. Pediococcus pentosaceus xy46 can absorb zearalenone and alleviate its toxicity to the reproductive systems of male mice. Microorganisms 7(8), 1–18 (2019).
  Google Scholar
• 34. Deng R, Wang SM, Yin T et al. Dimethyl sulfoxide suppresses mouse 4T1 breast cancer growth by modulating tumor-associated macrophage differentiation. J. Breast Cancer 17(1), 25–32 (2014).
  MedlineGoogle Scholar
• 35. Yang S, Zhang JJ, Huang XY. Mouse models for tumor metastasis. Methods Mol. Biol. 928, 221–228 (2012).
  Medline CASGoogle Scholar
• 36. Hong X, Liu Y, Hu G et al. EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Sci. 100(5), 961–969 (2009).
  Medline CASGoogle Scholar
• 37. Rajeh MA, Kwan YP, Zakaria Z, Latha LY, Jothy SL, Sasidharan S. Acute toxicity impacts of Euphorbia hirta L extract on behavior, organs body weight index and histopathology of organs of the mice and Artemia salina. Pharmacognosy Res. 4(3), 170–177 (2012).
  MedlineGoogle Scholar
• 38. Burggren W, Rojas Antich M. Angiogenesis in the avian embryo chorioallantoic membrane: a perspective on research trends and a case study on toxicant vascular effects. J. Cardiovasc. Dev. Dis. 7(4), 56 (2020).
  Medline CASGoogle Scholar
• 39. Chaudhary S, Garg T, Murthy RS, Rath G, Goyal AK. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int. J. Pharm. 485(1–2), 108–121 (2015).
  Medline CASGoogle Scholar
• 40. Northcott PA, Jones DT, Kool M et al. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12(12), 818–834 (2012).
  Medline CASGoogle Scholar
• 41. Wang HY, Yang SL, Liang HF, Li CH. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int. J. Mol. Sci. 15(3), 3507–3518 (2014).
  Medline CASGoogle Scholar
• 42. El-Tanani M, Nsairat H, Aljabali AA et al. Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis. Life Sci. 323, 121662 (2023).
  Medline CASGoogle Scholar
• 43. Williamson T, Mendes TB, Joe N, Cerutti JM, Riggins GJ. Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer. Endocr. Relat. Cancer 27(3), 123–136 (2020). •• This novel preclinical study of mebendazole in thyroid cancer has promising therapeutic implications for patients with treatment-refractory papillary or anaplastic thyroid cancer.
  Medline CASGoogle Scholar
• 44. Mohi-Ud-Din R, Chawla A, Sharma P et al. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects. Eur. J. Med. Res. 28(1), 345 (2023). •• Repurposing approved drugs can significantly expedite the process of identifying effective treatments and improve patient outcomes in a cost-effective manner.
  MedlineGoogle Scholar